David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients

Margaret O'Donnell, MD, of the City of Hope National Medical Center, summarizes a session on this vital topic (Session 613).

Multiple Myeloma

S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.

Lymphoma

Ronald Go, MD

Ronald Go, MD, on Survival in NHL and Treatment Facility Volume

Ronald Go, MD, of the Mayo Clinic, discusses a study that used the National Cancer Data Base to determine the extent to which the number of non-Hodgkin lymphoma patients treated annually in a facility affects overall survival (Abstract 266).

Lymphoma

Julie Vose, MD, MBA, and David Straus, MD

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and David Straus, MD, of Memorial Sloan Kettering Cancer Center, discuss the initial results of the U.S. Intergroup Trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for nonbulky stage I and II Hodgkin lymphoma (Abstract 578).

Lymphoma

Simon Rule, MD

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).

Feb

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Margaret O'Donnell, MD, on Novel Approaches to Treatment for Older AML Patients

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

Ronald Go, MD, on Survival in NHL and Treatment Facility Volume

Julie Vose, MD, MBA, and David Straus, MD, on Hodgkin Lymphoma Study Results: CALGB/Alliance 50604

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Multiple Myeloma FDA Approves Daratumumab and Hyaluronidase-fihj in Combination With VRd

FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials

New Biomarker May Predict Chemotherapy Response in Patients With Triple-Negative Breast Cancer

Acral Melanoma Ancestry and Genetics Impact Outcomes

Inequalities in Use of Minimally Invasive Surgical Resection in Colon Cancer